-+ 0.00%
-+ 0.00%
-+ 0.00%

Enlivex says FDA grants RMAT designation for Allocetra in age-related knee osteoarthritis

PUBT·07/13/2026 12:05:26
Listen to the news
Enlivex says FDA grants RMAT designation for Allocetra in age-related knee osteoarthritis
  • FDA granted RMAT designation to Allocetra for age-related symptomatic knee osteoarthritis in patients aged 64 and older.
  • Designation supports an expedited development path, including potential eligibility for accelerated approval or priority review.
  • Phase IIb trial targets 182 patients in the US and EU; top-line data expected by end of Q2 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enlivex Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077364), on July 13, 2026, and is solely responsible for the information contained therein.